Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04555031 · ClinicalTrials.gov registry record · NA

Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses

A NA study of Habitual Soft Contact Lens Use, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT04555031 is a NA study of Habitual Soft Contact Lens Use that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04555031, a NA study of Habitual Soft Contact Lens Use, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Approximately 20 habitual soft contact lens wearing participants will be enrolled in this unilateral, randomized, double-masked (participant and investigator masked) repeated measures insertion study. All participants will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If participants satisfy all eligibility criteria and none of the exclusion criteria, subjects will insert study lenses in random, successive order according to unique randomization schedules that will be provided to each Investigator.

Interventions

  • DEVICE kalifilcon A lenses
  • DEVICE Dalies Total 1
  • DEVICE Precision 1
  • DEVICE Biotrue ONEday

Study Locations (1)

New York

  • Bausch and Lomb Site 01 - Rochester

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-09-09
Est. Completion 2020-09-16
Phase NA

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT04555031

The ClinicalTrials.gov registry entry for NCT04555031 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Habitual Soft Contact Lens Use appearing as the primary indexed condition, and to 4 interventions - of which kalifilcon A lenses is the first listed.

NCT04555031 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04555031 about?

NCT04555031 is a clinical study titled "Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses". Approximately 20 habitual soft contact lens wearing participants will be enrolled in this unilateral, randomized, double-masked (participant and investigator masked) repeated measures insertion study. All participants will be seen for a Screening/Dispensing Visit at which informed consent will be ob...

What is the current status of trial NCT04555031?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2020-09-09. Estimated completion is 2020-09-16.

What conditions does trial NCT04555031 study?

This clinical trial studies the following conditions: Habitual Soft Contact Lens Use.

What interventions are being tested in trial NCT04555031?

The interventions under investigation include: kalifilcon A lenses (DEVICE), Dalies Total 1 (DEVICE), Precision 1 (DEVICE), Biotrue ONEday (DEVICE).

Who is sponsoring clinical trial NCT04555031?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04555031 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.